| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/1078-0432.CCR-08-1158 |
| P698 | PubMed publication ID | 19228740 |
| P2093 | author name string | Jun Li | |
| Ling Zhang | |||
| Wen Li | |||
| Mu-Sheng Zeng | |||
| Mengfeng Li | |||
| Li-Bing Song | |||
| Chun-Ping Yu | |||
| Gui-Xiang Weng | |||
| Yi-xin Zeng | |||
| Jin-tang Xia | |||
| Qing-li Kong | |||
| Li-juan Hu | |||
| Hai-qing Zheng | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| P304 | page(s) | 1393-1399 | |
| P577 | publication date | 2009-02-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Sphingosine kinase 1 is associated with gastric cancer progression and poor survival of patients | |
| P478 | volume | 15 |
| Q50074651 | A selective sphingosine-1-phosphate receptor 1 agonist SEW-2871 aggravates gastric cancer by recruiting myeloid-derived suppressor cells |
| Q36251372 | A20 suppresses hepatocellular carcinoma proliferation and metastasis through inhibition of Twist1 expression |
| Q52663621 | ABCC1-Exported Sphingosine-1-phosphate, Produced by Sphingosine Kinase 1, Shortens Survival of Mice and Patients with Breast Cancer. |
| Q39109984 | AKT activation drives the nuclear localization of CSE1L and a pro-oncogenic transcriptional activation in ovarian cancer cells. |
| Q35568516 | Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. |
| Q54646109 | Antiangiogenic agents and targets: A perspective |
| Q37190258 | Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. |
| Q34365926 | Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics |
| Q43753628 | Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study |
| Q43490599 | Clinical significance of annexin II expression in human non-small cell lung cancer |
| Q91693306 | Colon Cancer and Perturbations of the Sphingolipid Metabolism |
| Q38619642 | DNA damage response and sphingolipid signaling in liver diseases |
| Q35754223 | Defining a role for sphingosine kinase 1 in p53-dependent tumors. |
| Q30426812 | Development of amidine-based sphingosine kinase 1 nanomolar inhibitors and reduction of sphingosine 1-phosphate in human leukemia cells |
| Q37364111 | Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling. |
| Q36827749 | Downregulation of DHRS9 expression in colorectal cancer tissues and its prognostic significance. |
| Q47588678 | Etoposide Upregulates Survival Favoring Sphingosine-1-Phosphate in Etoposide-Resistant Retinoblastoma Cells |
| Q91854913 | Evaluation of binding and inhibition mechanism of dietary phytochemicals with sphingosine kinase 1: Towards targeted anticancer therapy |
| Q26863646 | Evolving concepts in cancer therapy through targeting sphingolipid metabolism |
| Q27009557 | Export of sphingosine-1-phosphate and cancer progression |
| Q53309734 | Hair Cell Loss Induced by Sphingosine and a Sphingosine Kinase Inhibitor in the Rat Cochlea. |
| Q33275396 | High expression of SPHK1 in sacral chordoma and association with patients' poor prognosis |
| Q35583857 | High expression of Talin-1 is associated with poor prognosis in patients with nasopharyngeal carcinoma. |
| Q40964594 | High levels of sphingolipids in human breast cancer. |
| Q36414244 | Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma. |
| Q53256892 | Immunohistochemical Detection of Sphingosine-1-Phosphate and Sphingosine Kinase-1 in Human Tissue Samples and Cell Lines. |
| Q38394714 | Increased SPHK1 expression is associated with poor prognosis in bladder cancer |
| Q51051446 | Increased expression of FOXQ1 is a prognostic marker for patients with gastric cancer. |
| Q44697049 | Increased radiation sensitivity of head and neck squamous cell carcinoma with sphingosine kinase 1 inhibition. |
| Q34373466 | Interdiction of sphingolipid metabolism to improve standard cancer therapies |
| Q37100281 | Interstitial Fluid Sphingosine-1-Phosphate in Murine Mammary Gland and Cancer and Human Breast Tissue and Cancer Determined by Novel Methods |
| Q38316610 | Introducing biomarker panel in esophageal, gastric, and colon cancers; a proteomic approach |
| Q34540244 | Loss of sphingosine kinase-1 in carcinoma cells increases formation of reactive oxygen species and sensitivity to doxorubicin-induced DNA damage |
| Q34165938 | Lysophosphatidic acid stimulates gastric cancer cell proliferation via ERK1-dependent upregulation of sphingosine kinase 1 transcription. |
| Q37154242 | Mechanisms linking obesity and cancer |
| Q38969211 | Metabolic Regulation of Apoptosis in Cancer. |
| Q37045562 | MiR-24 enhances radiosensitivity in nasopharyngeal carcinoma by targeting SP1. |
| Q92591768 | MicroRNA-9 exerts antitumor effects on hepatocellular carcinoma progression by targeting HMGA2 |
| Q36621591 | Migration of gastric cancer cells in response to lysophosphatidic acid is mediated by LPA receptor 2 |
| Q35955451 | Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer |
| Q36234717 | Oncogenic K-Ras regulates bioactive sphingolipids in a sphingosine kinase 1-dependent manner |
| Q38092176 | Oncogenic properties of sphingosine kinases in haematological malignancies. |
| Q34048461 | Overexpression of GOLPH3 is associated with poor prognosis and clinical progression in pancreatic ductal adenocarcinoma |
| Q33693882 | Overexpression of sphingosine kinase 1 is associated with salivary gland carcinoma progression and might be a novel predictive marker for adjuvant therapy |
| Q40978323 | Overexpression of sphingosine kinase 1 is predictive of poor prognosis in human breast cancer |
| Q43268349 | PDE5 Overexpression in Well-Differentiated Thyroid Carcinomas Is Associated with Lymph Node Metastasis. |
| Q91272135 | POTEE drives colorectal cancer development via regulating SPHK1/p65 signaling |
| Q90371583 | PRDM3 attenuates pancreatitis and pancreatic tumorigenesis by regulating inflammatory response |
| Q88961948 | Preclinical study of the antitumor effect of sphingosine-1-phosphate receptor 1 antibody (S1PR1-antibody) against human breast cancer cells |
| Q47193833 | Predictive and prognostic value of sphingosine kinase 1 expression in patients with invasive ductal carcinoma of the breast |
| Q37514093 | Rab14 Suppression Mediated by MiR-320a Inhibits Cell Proliferation, Migration and Invasion in Breast Cancer. |
| Q33649823 | Re-configuration of sphingolipid metabolism by oncogenic transformation |
| Q85888649 | Reduced expression of Dicer11 is associated with poor prognosis in patients with nasopharyngeal carcinoma |
| Q35817821 | Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer |
| Q92889972 | Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1 |
| Q46642305 | Role of Brf1 interaction with ERα, and significance of its overexpression, in human breast cancer |
| Q34017124 | Role of sphingosine kinase-1 in paracrine/transcellular angiogenesis and lymphangiogenesis in vitro. |
| Q34879183 | Roles of sphingosine 1-phosphate on tumorigenesis |
| Q89587308 | S1P Signaling in the Tumor Microenvironment |
| Q26998940 | STAT3 and sphingosine-1-phosphate in inflammation-associated colorectal cancer |
| Q90615572 | SWELL1 promotes cell growth and metastasis of hepatocellular carcinoma in vitro and in vivo |
| Q35496844 | Serine threonine tyrosine kinase 1 is a potential prognostic marker in colorectal cancer |
| Q64052458 | Significance of sphingosine kinase 1 expression in feline mammary tumors |
| Q34105169 | SphK1 confers resistance to apoptosis in gastric cancer cells by downregulating Bim via stimulating Akt/FoxO3a signaling |
| Q42746891 | Sphingosine 1-Phosphate Receptor 2 Regulates the Migration, Proliferation, and Differentiation of Mesenchymal Stem Cells |
| Q34121255 | Sphingosine 1-phosphate and cancer |
| Q35108994 | Sphingosine kinase 1 and cancer: a systematic review and meta-analysis |
| Q33853998 | Sphingosine kinase 1 in cancer |
| Q27853204 | Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer |
| Q33636769 | Sphingosine kinase 1 is overexpressed and promotes proliferation in human thyroid cancer |
| Q34428778 | Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation |
| Q36621483 | Sphingosine kinase 1 is upregulated with lysophosphatidic acid receptor 2 in human colorectal cancer. |
| Q33631908 | Sphingosine kinase 1 isoform-specific interactions in breast cancer |
| Q90326756 | Sphingosine kinase 1 overexpression contributes to sunitinib resistance in clear cell renal cell carcinoma |
| Q37614489 | Sphingosine kinase 1 promotes malignant progression in colon cancer and independently predicts survival of patients with colon cancer by competing risk approach in South asian population |
| Q33598751 | Sphingosine kinase 1: A novel independent prognosis biomarker in hepatocellular carcinoma |
| Q50021960 | Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice |
| Q28069459 | Sphingosine-1 Phosphate: A New Modulator of Immune Plasticity in the Tumor Microenvironment |
| Q36627430 | Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. |
| Q38967180 | Sphingosine-1-phosphate mediates a reciprocal signaling pathway between stellate cells and cancer cells that promotes pancreatic cancer growth |
| Q42181059 | Sphingosine-1-phosphate transporters as targets for cancer therapy. |
| Q34678040 | Sphingosine‐1‐phosphate antibodies as potential agents in the treatment of cancer and age‐related macular degeneration |
| Q37905015 | Still benched on its way to the bedside: sphingosine kinase 1 as an emerging target in cancer chemotherapy |
| Q89284626 | Stress, inflammation, and eicosanoids: an emerging perspective |
| Q35831148 | TGFβ-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis |
| Q49714600 | TP53 is required for BECN1- and ATG5-dependent cell death induced by sphingosine kinase 1 inhibition |
| Q35789935 | Targeting sphingosine kinase-1 to inhibit melanoma. |
| Q39379449 | Targeting sphingosine-1-phosphate signaling for cancer therapy |
| Q26748927 | The emerging role of FTY720 (Fingolimod) in cancer treatment |
| Q34902490 | The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells |
| Q90536694 | The significance of Runx2 mediating alcohol-induced Brf1 expression and RNA Pol III gene transcription |
| Q34986940 | The sphingosine kinase 1/sphingosine-1-phosphate pathway in pulmonary arterial hypertension |
| Q38915115 | Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism |
| Q37930972 | Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer |
| Q35877252 | Upregulation of NETO2 expression correlates with tumor progression and poor prognosis in colorectal carcinoma |
| Q39373595 | miR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. |
Search more.